Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,409 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Tumor Clear all
Completed Phase 2 Interventional

Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate

NCT00006332
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 5:17 AM EDT
Completed No phase listed Observational

Examination of the Pancreas in New-onset Diabetes

NCT02001337
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
medical chart review, survey administration, Specimen collection
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 2, 2026, 5:17 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1 and 2 Study of PX-866 and Cetuximab

NCT01252628
View directory record Official record
Conditions
Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions
PX-866 (SCCHN), Cetuximab (SCCHN), PX-866 (CRC), Cetuximab (CRC)
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Birmingham, Alabama • Escondido, California • Monterey, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 2, 2026, 5:17 AM EDT
Completed No phase listed Observational

Hereditary Colorectal and Associated Tumor Registry Study

NCT00633607
View directory record Official record
Conditions
Lynch Syndrome, FAP, Hereditary Diffuse Gastric Cancer, Juvenile Polyposis Syndrome, Peutz-Jeghers Syndrome
Interventions
Research Registry
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 100 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 2, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

NCT03790111
View directory record Official record
Conditions
Biliary Tract Cancer (BTC)
Interventions
telotristat ethyl
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Gilbert, Arizona • Fullerton, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 2, 2026, 5:17 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

NCT06410534
View directory record Official record
Conditions
Colorectal Cancer, Gastroesophageal Cancer
Interventions
nivolumab, ipilimumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 2, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional

Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus

NCT00239200
View directory record Official record
Conditions
Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus
Interventions
Lapatinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 2, 2026, 5:17 AM EDT
Completed No phase listed Observational

Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice

NCT02277834
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 2, 2026, 5:17 AM EDT
Completed Not applicable Interventional Results available

Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV

NCT01946139
View directory record Official record
Conditions
Anal Cancer, HIV Infection, Human Papilloma Virus Infection
Interventions
comparison of screening methods, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Procedure · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 2, 2026, 5:17 AM EDT
Completed No phase listed Observational

Registry to Collect Health Information Related to Fibrolamellar Cancer

NCT04874519
View directory record Official record
Conditions
Fibrolamellar Cancer, FLC, Liver Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 2, 2026, 5:17 AM EDT
Completed Phase 3 Interventional

Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial

NCT00509444
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Cancer, Prostate Cancer, Lung Cancer
Interventions
Educational materials, educational materials, plus patient navigation
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 2, 2026, 5:17 AM EDT
Completed Phase 2 Interventional

SU011248 in Advanced Hepatocellular Carcinoma

NCT00361309
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
SU011248
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 2, 2026, 5:17 AM EDT
Not listed Phase 2 Interventional

DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer

NCT00024375
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
DHA-paclitaxel
Drug
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Oct 2, 2026, 5:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Different Carbohydrate Feedings on a Hydrogen Breath Curve and Self-reported Gastrointestinal Complaints

NCT06648967
View directory record Official record
Conditions
Quality of Life
Interventions
Supplementation with a multi-ingredient whey supplement
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 2, 2026, 5:17 AM EDT
Active, not recruiting Phase 3 Interventional

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 2, 2026, 5:17 AM EDT
Active, not recruiting Phase 2 Interventional

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

NCT06699836
View directory record Official record
Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 5:17 AM EDT
Terminated No phase listed Observational

WavSTAT® Optical Biopsy System to Target Esophageal Biopsies

NCT00747136
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Not listed
Lead sponsor
SpectraScience
Other
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 2, 2026, 5:17 AM EDT
Completed Phase 1 Interventional

Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management

NCT02199236
View directory record Official record
Conditions
Rectal or Anal Cancer
Interventions
endorectal brachytherapy, concurrent capecitabine or 5-FU, Questionnaires
Radiation · Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 2, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Results available

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

NCT05169437
View directory record Official record
Conditions
Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
Interventions
Niraparib
Drug
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
80
States / cities
Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 2, 2026, 5:17 AM EDT
Not yet recruiting Not applicable Interventional

Enhancing Screening Practices for BE

NCT07335445
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Screening Reminder
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 2, 2026, 5:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Urine Metabolites in the Diagnosis of Disease

NCT06710067
View directory record Official record
Conditions
Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
Interventions
Not listed
Lead sponsor
Luventix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Encinitas, California • Santa Monica, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 2, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

NCT01896531
View directory record Official record
Conditions
Gastric Cancer
Interventions
5-Fluorouracil, Ipatasertib, Leucovorin, Oxaliplatin, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 2, 2026, 5:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Financial Incentives to Increase Colorectal Cancer Screening in Priority Populations

NCT03080701
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Auto Mailing Plus Money, Auto Mailing Plus Lottery
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 75 Years
Enrollment
898 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 2, 2026, 5:17 AM EDT
Completed Phase 1Phase 2 Interventional

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

NCT01206530
View directory record Official record
Conditions
Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
Interventions
Hydroxychloroquine, Oxaliplatin, Leucovorin, 5-fluorouracil, Bevacizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 2, 2026, 5:17 AM EDT